The first Russian vaccine against coronavirus, developed by military experts and scientists from the Gamaley National Research Center, is ready, Deputy Defense Minister Ruslan Tsalikov said in an interview with Argumenti I F.
"Our experts and scientists from the Gamaley National Research Center have made the final evaluations of the clinical trials. At the time of the outbreak, all the volunteers, without exception, having acquired immunity to the coronavirus, felt normal. "In this way, the first Russian vaccine for the new coronavirus is ready," Tsalikov said.
The Russian Ministry of Defense announced that together with the National Research Center for Epidemiology and Microbiology Gamalei successfully completed the clinical trials of the coronavirus vaccine, which were carried out at the Burdenko military hospital with the participation of 43 volunteers.
For his part, Vladimir Nikoforov, chief infectious disease specialist at the Russian Federal Medical Biological Service and chair of infectious diseases at Pirogov Medical University, said it would take about 18 months to develop a viable embryo.
"It usually takes at least 18 months to develop a truly viable vaccine that has been tested for efficacy and safety. This is the reference point. "When we try it, we will see if it is effective," he said.
According to the expert, the new virus has come to stay and is unlikely to disappear. He has two possible ways for the future. "Either it degrades to an acute respiratory infection, like its predecessors - we know of four coronaviruses that have caused colds - and it will be the fifth. "Or it will acquire a nature of seasonal flu, that is, it will come in the fall, causing serious illness and disappear by the summer," he said. "But, obviously, there will be no such cases as there are in winter and spring."
Meanwhile, the American companies Pfizer, Merck and Moderna confirmed information that they will not sell at a price the possible vaccines against the new coronavirus that they will prepare, during a hearing in the US Congress. Instead, Johnson & Johnson and AstraZeneca pledged to market their own vaccines in the first place without any benefit.
Many companies have received hundreds of millions of dollars in grants from the US government or other countries. However, the agreements they signed did not include conditions relating to the maximum price of their potential vaccine. "We will not sell at cost," Moderna president Steven Hogg said in response to a question from a lawmaker. The biotechnology company is said to be developing one of the most advanced experimental vaccines.
Source: "The Liberal"